Loading stock…

McKesson Corporation (MCK) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

McKesson Corporation

MCKMarket cap $108BPrice $930.3

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Distributes prescription drugs and medical supplies to 99% of US hospitals and 95% of pharmacies. Handles one-third of all pharmaceuticals flowing through North America, making it healthcare's invisible backbone.

In Bastion Portfolios?

52W Return+19%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+13%8

Revenue Forecast

Rev CAGR (1y)+7%5

Rev CAGR (3y)+7%5

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1+16%8

EPS Growth Y+2+10%7

EPS Growth Y+3+10%7

Quality

Margins

EBIT Margin2%2

Net Income Margin1%2

Free Cash Flow Margin2%3

Debt

Net Debt/EBITDA0.96

Efficiency

ROEna–

ROA6%7

Earnings Stability88

GEAR+AVERAGE57

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)204

P/E Ratio (Forward 3y)174

P/BVna–

EV Multiples

EV/EBITDA Fwd153

EV/EBIT Fwd165

Yield

Free Cash Flow Yield5.9%7

Dividend Yield0.4%1

Momentum

Short term

1 month return+4%9

3 month return+17%9

YTD return+14%7

Mid term

Price vs 52wHigh93%9

1 year return+23%7

Long term

3 year return+109%8

5 year return+377%10

Risk Shield

Price Risk

Beta0.110

Volatility30%7

Free Cash Flow

Free Cash Flow Margin2%3

Free Cash Flow Yield5.9%7

Quality

ROCE37%10

Earnings Stability88

Net Debt/EBITDA0.96

02Growth

Is it actually growing, and how fast?

MCKMcKesson

Revenue FY26$403B

GROWTH RATING↗

AVERAGE55 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+16%8

EPS growth, FY28E+10%7

EPS growth, FY29E+10%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 55% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 13%/yr over the last 3 years; forecasts see it cooling to 7%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG95 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return+17%9

YTD return+14%7

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return+23%7

3-year return+109%8

5-year return+377%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +109% over three years and +377% over five, ahead of 80% of the market.

It's up 23% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+4%), over three months (+17%) and so far this year (+14%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on McKesson. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MCKMcKesson

Revenue FY26$403B

GROWTH RATING↗

AVERAGE55 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+16%8

EPS growth, FY28E+10%7

EPS growth, FY29E+10%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 55% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 13%/yr over the last 3 years; forecasts see it cooling to 7%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG95 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return+17%9

YTD return+14%7

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return+23%7

3-year return+109%8

5-year return+377%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +109% over three years and +377% over five, ahead of 80% of the market.

It's up 23% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+4%), over three months (+17%) and so far this year (+14%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on McKesson. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community